Daily Newspaper

Vaccine-in COVID-19 avanga thih theihna risk 99%-in a tihniam

23

Times of India-in a tarlan danin Pune a National Institute of Virology (NIV)-a mithiam ten zirchianna neiin, COVID-19 vaccine dose hnih la tawh chung pawha hri kai an awm thona chhan te an zirchiang a, hetihrual hian COVID-19 vaccine hian COVID-19 Delta strain avanga thih theihna risk chu 99% -in a tihniam niin an sawi bawk.

He zirchianna atanga an hmuh dan chuan sample tam zawk chu Delta variant a ni a, chutihrualin variant chi dang Al- pha, Kappa, Delta AY.1 (Delta plus an tih bawk) leh Delta AY.2 te pawh a tel tho bawk.

Vaccine dose hnih la tawh chunga COVID-19 hri an kai hi ‘breakthrough infection’ an ti a, zirchianna neitute chuan tuna hrileng kan kai nasat ber Delta variant hi nikum Octo- ber-a hmuhchhuah tawh kha niin, hei hi tuna second wave kan tih mai rawn thlentu niin an sawi. Zirchianna neitu te zinga an hotu pakhat Dr Yadav chuan, “Tunah chuan Delta variant hi khawvel pumah a darh tawh a, mahse, kan zirchianna atanga a point pawimawh ta ber chu vaccine lak hian inkaichhawn awlsam leh thawk na zawk, Delta strain avanga thih theihna risk 99%- inatihniamtihhiani,”ati.

He zirchianna atanga an hmuh pakhat chu vaccine la tawh chunga hrikai ten an kai tam ber chu Delta variant hi a ni a, mahse, vaccine la tawh zinga 9.8% chauh damdawi ina enkawl ngai an ni a, vaccine dose hnih la tawh zinga hrikai thi chu 0.4% an ni. Hei hian vaccine lak hian COVID-19 avanga damdawi in awm leh thih theihna risk a tihniam tih a tilang chiang niin an ngai a ni.

He zirchiannaa sample an hman te hi an kum upat dan chawhrual chu kum 44 a ni a, 65.1% chu mipa niin, 71% chuan symptom nasa lo pahnih khat chauh an nei. Khawsik chu a symp- tom zinga langsar ber niin 69% a ni a, taksa kham na deuh them thum, lu na leh luak chhuak chu a dawttu niin, hetiang symptom nei hi 56% an awm a, khuh (45%) leh hrawk na (37%) an awm bawk.

Get real time updates directly on you device, subscribe now.

Leave A Reply

Your email address will not be published.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy